Phase III study of PSC‐833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): A trial of the Eastern Cooperative Oncology Group
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Preliminary studies have shown valspodar (PSC‐833: Novartis Pharmaceuticals, East Hanover, NJ) to be a potent inhibitor of multidrug resistance (MDR), one cause of resistance to chemotherapy. An international randomized control study (Phase III) evaluated the use of vincristine, doxorubicin, and dexamethasone (VAD) with (n = 46) and without (n = 48) valspodar in the treatment of patients with recurring or refractory multiple myeloma. METHODS: Patients with documented recurrence or refractory myeloma were stratified based on prior treatment exposure and creatinine and randomized. Because of interaction of valspodar with vincristine and doxorubicin, the doses of these drugs were reduced compared with the VAD‐alone arm, and the doxorubicin was further reduced in the last 15 patients when given with valspodar based on pharmacokinetic and toxicity studies. RESULTS: There were no complete or near‐complete responses. There were 29% partial responses (PRs) in the VAD‐alone arm and 44% with valspodar (P = 0.2). Median progression‐free survival was 7 months with VAD alone and 4.9 months with valspodar (P = 0.50). Subjective response was 19% with VAD alone and 17% with valspodar (P = 1.0). Median survival with VAD alone was 18.5 months and 15.3 with the addition of valspodar (P = 0.055). Toxicity of Grade 3 or greater was higher (P < 0.0001) in the valspodar arm (89%) compared with the VAD‐alone arm (58%). The reduction of doxorubicin dose reduced toxicity but not significantly (P = 0.11). CONCLUSION: The addition of the MDR‐modulating agent valspodar to VAD did not improve treatment outcome. Toxicity was increased in the valspodar‐treated group compared with VAD alone. Cancer 2006. © 2006 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Transplantation for multiple myeloma: who, when, how often?
(2003) · Blood · doi:10.1182/blood-2003-01-0073 · Cited by 88 · cited 2×
“Complete response 0 (0) 0 (0) Near complete response 0 (0) 0 (0) Partial response 14 (29) 20 (44) No change 25 (52) 14 (30) Progressive disease 3 (6) 3 (6) Inevaluable 2 (4) 8 (17) Unknown 4 (8) 1 (2)”
Cited by
An overview of cancer multidrug resistance: a still unsolved problem
Lage, H. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8111-5 · Cited by 408
Cancer stem cells: The root of tumor recurrence and metastases
Peitzsch, C., Tyutyunnykova, A., Pantel, K., & Dubrovska, A. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.02.011 · Cited by 372
Marchetti, S., Mazzanti, R., Beijnen, J. H., & Schellens, J. H. M. (2007) · The Oncologist · doi:10.1634/theoncologist.12-8-927 · Cited by 284
Wu, C., Calcagno, A. M., & Ambudkar, S. V. (2008) · Current Molecular Pharmacology · doi:10.2174/1874-470210801020093 · Cited by 259
Development of inhibitors of ATP-binding cassette drug transporters – present status and challenges
Shukla, S., Wu, C.-P., & Ambudkar, S. V. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.2.205 · Cited by 253
The controversial role of ABC transporters in clinical oncology
Tamaki, A., Ierano, C., Szakacs, G., Robey, R. W., & Bates, S. E. (2011) · Essays in Biochemistry · doi:10.1042/bse0500209 · Cited by 235
Revisiting the ABCs of Multidrug Resistance in Cancer Chemotherapy
K. Tiwari, A., Sodani, K., Dai, C.-L., R. Ashby, C., & Chen, Z.-S. (2011) · Current Pharmaceutical Biotechnology · doi:10.2174/138920111795164048 · Cited by 211
Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms
Abdi, J., Chen, G., & Chang, H. (2013) · Oncotarget · doi:10.18632/oncotarget.1497 · Cited by 172
Lai, J.-I., Tseng, Y.-J., Chen, M.-H., Huang, C.-Y. F., & Chang, P. M.-H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.561936 · Cited by 144
ABC Transporters: Unvalidated Therapeutic Targets in Cancer and the CNS
W. Robey, R., R. Massey, P., Amiri-Kordestani, L., & E. Bates, S. (2010) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152010794473957 · Cited by 85
Acquisition of a multidrug-resistant phenotype with a proteasome inhibitor in multiple myeloma
Gutman, D., Morales, A. A., & Boise, L. H. (2009) · Leukemia · doi:10.1038/leu.2009.123 · Cited by 53
Targeting NF-κB Signaling for Multiple Myeloma
Wong, A. H.-H., Shin, E. M., Tergaonkar, V., & Chng, W.-J. (2020) · Cancers · doi:10.3390/cancers12082203 · Cited by 42
Ravindranathan, P., Pasham, D., & Goel, A. (2019) · Carcinogenesis · doi:10.1093/carcin/bgy184 · Cited by 35
Metadata
- Authors
- Friedenberg, W. R., Rue, M., Blood, E. A., Dalton, W. S., Shustik, C., Larson, R. A., Sonneveld, P., & Greipp, P. R.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2006-02-03
- Volume
- 106
- Issue
- 4
- Pages
- 830-838
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2067815150
- Cited by
- 146
- References
- 1
- FWCI
- 5.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.